Inclusion Criteria:

• Participant must self-identify as being of Middle Eastern or African descent.

• Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive.

  • Melanoma is allowed; sarcoma is not eligible.
  • Secondary malignancies are allowed.
  • Participants who have received only surgery alone as treatment are eligible

• Participant must be between the ages of 18-80.

• Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it.

Exclusion Criteria:

• Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics.

  • Participants may be eligible for the study if the infection is deemed to be under control per investigator's discretion.

• Participants who have ever received cytotoxic chemotherapy.

  • Those who have already started a chemotherapy regimen with moderate likelihood of developing neutropenia will be considered for enrollment at the principal investigator's discretion.

• Participants who are receiving concurrent chemo-radiation treatment.

• Participants who are taking any other investigational drugs.

• Participants who are pregnant or breastfeeding.

• Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan.